GlaxoSmithKline and Theravance, 642444 and 685698 advance in clinical development for the treatment of asthma

Jan. 03, 2008 - GlaxoSmithKline Plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced the start of large Phase 2b asthma dose-optimisation studies with both the lead inhaled corticosteroid (ICS) GW685698 ('698) and the lead long-acting beta agonist (LABA) GW642444 ('444) assets in the 'Horizon' programme to develop a next-generation combination product. GSK began enrolling patients with mild to severe asthma in the '698 Phase 2b clinical programme on 21st December 2007 and began enrolling patients with persistent asthma in the '444 Phase 2b clinical programme on 29th December 2007. These clinical programmes will determine the most effective doses to be taken into Phase 3 combination studies. The Phase 2b COPD programme with '444 is also on schedule to commence in 1H 2008... GSK's Press Release - Theravance's Press Release-